| __timestamp | Johnson & Johnson | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22746000000 | 94103000 |
| Thursday, January 1, 2015 | 21536000000 | 146194000 |
| Friday, January 1, 2016 | 21685000000 | 130000 |
| Sunday, January 1, 2017 | 25354000000 | 7353000 |
| Monday, January 1, 2018 | 27091000000 | 34193000 |
| Tuesday, January 1, 2019 | 27556000000 | 56586000 |
| Wednesday, January 1, 2020 | 28427000000 | 63382000 |
| Friday, January 1, 2021 | 23402000000 | 97049000 |
| Saturday, January 1, 2022 | 24596000000 | 139989000 |
| Sunday, January 1, 2023 | 26553000000 | 150343000 |
| Monday, January 1, 2024 | 27471000000 |
Unleashing the power of data
In the ever-evolving landscape of the pharmaceutical industry, understanding cost dynamics is crucial. Johnson & Johnson, a stalwart in the sector, has consistently maintained a robust cost of revenue, averaging around $24.9 billion annually from 2014 to 2023. This reflects a steady growth trajectory, with a notable peak in 2020, where costs surged by approximately 25% compared to 2014.
In contrast, Sarepta Therapeutics, Inc., a burgeoning biotech firm, presents a different narrative. Starting with a modest cost of revenue of $94 million in 2014, Sarepta has seen a dramatic increase, reaching $150 million by 2023. This represents a staggering growth of over 60% in just under a decade.
These trends highlight the contrasting scales and growth strategies of established giants versus emerging innovators in the pharmaceutical world.
Comparing Cost of Revenue Efficiency: Eli Lilly and Company vs Johnson & Johnson
Johnson & Johnson vs Merck & Co., Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Johnson & Johnson vs Amgen Inc.
Cost of Revenue Trends: Johnson & Johnson vs Neurocrine Biosciences, Inc.
Cost Insights: Breaking Down Johnson & Johnson and PTC Therapeutics, Inc.'s Expenses
Cost of Revenue: Key Insights for Johnson & Johnson and Mesoblast Limited
Cost of Revenue Trends: Johnson & Johnson vs Viridian Therapeutics, Inc.
Cost of Revenue: Key Insights for GSK plc and Sarepta Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Sarepta Therapeutics, Inc. vs Exelixis, Inc.
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and ADMA Biologics, Inc.'s Expenses
Cost of Revenue Comparison: Sarepta Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc.
Cost of Revenue Comparison: Sarepta Therapeutics, Inc. vs HUTCHMED (China) Limited